{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:31:23Z","timestamp":1772148683325,"version":"3.50.1"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0220142","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T17:41:59Z","timestamp":1563990119000},"page":"e0220142","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-0963","authenticated-orcid":true,"given":"Saara","family":"Huoponen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalle J.","family":"Aaltonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaana","family":"Viikinkoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarno","family":"Rutanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heikki","family":"Relas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Taimen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Puolakka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"ref1","unstructured":"Rheumatoid Arthritis (online). Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Society for Rheumatology. 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.kaypahoito.fi\" xlink:type=\"simple\">http:\/\/www.kaypahoito.fi<\/ext-link> (accessed December 21, 2018)."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"KJ Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"S Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"JL Nam","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","article-title":"The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"YH Lee","year":"2011","journal-title":"Rheumatol Int"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"RF van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial","volume":"381","author":"C Gabay","year":"2013","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.21876","article-title":"Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study","volume":"65","author":"P Nash","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0119683","article-title":"The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: A systematic review","volume":"10","author":"JT Joensuu","year":"2015","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"kew467","DOI":"10.1093\/rheumatology\/kew467","article-title":"Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice","volume":"56","author":"KJ Aaltonen","year":"2017","journal-title":"Rheumatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S0266462309090230","article-title":"Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden","volume":"25","author":"P Lindgren","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.22151","article-title":"Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis","volume":"66","author":"JS Chen","year":"2014","journal-title":"Arthritis Care Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"MLL Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"ref15","first-page":"34","article-title":"Development and Validation of the European League Against Rheumatism Reponse Criteria for Rheumatoid Arhritis","volume":"39","author":"M van Gestel a","year":"1996","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"DTD Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"ref17","article-title":"Application instructions for health economic evaluation","year":"2018","journal-title":"Application instructions for health economic evaluation"},{"key":"ref18","first-page":"1","article-title":"Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland","author":"K Aaltonen","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy","volume":"42","author":"KJ Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"key":"ref20","first-page":"1","article-title":"Cost-effectiveness of biological compared with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Register study","author":"JT Joensuu","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","unstructured":"Official Statistics of Finland (OSF): Deaths in 2017 [e-publication]. ISSN = 1798\u20132545. Helsinki: Statistics Finland. 2018. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.tilastokeskus.fi\/til\/kuol\/tau.html\" xlink:type=\"simple\">http:\/\/www.tilastokeskus.fi\/til\/kuol\/tau.html<\/ext-link> (accessed October 8, 2018)."},{"key":"ref22","first-page":"1057","article-title":"Improvement in five-year mortality in rheumatoid arthritis compared to the general population\u2013closing the mortality gap","volume":"76","author":"D Lacaille","year":"2018","journal-title":"Improvement in five-year mortality in rheumatoid arthritis compared to the general population\u2013closing the mortality gap"},{"key":"ref23","first-page":"954","article-title":"No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset","author":"EJA Kroot","year":"2000","journal-title":"No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset"},{"key":"ref24","first-page":"11","article-title":"Mortality in rheumatoid arthritis patients with disease onset in the 1980s","volume":"1999","author":"E Lindqvist","journal-title":"Mortality in rheumatoid arthritis patients with disease onset in the 1980s"},{"key":"ref25","unstructured":"Ohinmaa A, Sintonen H. Inconsistencies and modelling of the Finnish EuroQol (EQ-5D) preference values. In: Greiner W, Graf v.d. Schulenburg J.-M, Piercy J, (Eds) EuroQol Plenary Meeting, Hannover 1998, 1st-2nd October, Discussion Papers. n.d."},{"key":"ref26","article-title":"Prices of authorised medicinal products with reimbursement status","year":"2018","journal-title":"Prices of authorised medicinal products with reimbursement status"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1186\/2193-1801-2-531","article-title":"Administration costs of intravenous biologic drugs for rheumatoid arthritis","volume":"2","author":"EJ Soini","year":"2013","journal-title":"Springerplus"},{"key":"ref28","article-title":"Terveyden- ja sosiaalihuollon yksikk\u00f6kustannukset Suomessa vuonna 2011","author":"S Kapiainen","year":"2014","journal-title":"Terveyden Ja Hyvinvoinnin Laitos"},{"key":"ref29","article-title":"Official Statistics of Finland (OSF): Price index of public expenditure [e-publication]","year":"2018"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/rheumatology\/39.2.122","article-title":"The links between joint damage and disability in rheumatoid arthritis","volume":"39","author":"DL Scott","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling Valuations for EuroQol Health States","volume":"35","author":"P. Dolan","year":"1997","journal-title":"Med Care"},{"key":"ref32","article-title":"Gross domestic product at market prices in 2017","year":"2018","journal-title":"Gross domestic product at market prices in 2017"},{"key":"ref33","first-page":"1","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor","author":"LR Harrold","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/annrheumdis-2011-200490","article-title":"Comparative effectiveness and safety of biological treatment options after tumour necrosis factor inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis","volume":"71","author":"M Schoels","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"a Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","article-title":"Comparative effectiveness and safety of rituximab versus subsequent anti\u2013tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti\u2013tumor necrosis factor therapies in the United States Corrona registry","volume":"17","author":"LR Harrold","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial","volume":"17","author":"SHM Manders","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kep425","article-title":"Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting","volume":"49","author":"TA Hallinen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref39","unstructured":"Finlex Data Bank. Health Insurance Act (1224\/2004), Chapter 6. n.d. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.finlex.fi\/fi\/laki\/ajantasa\/2004\/20041224#O2L6P7b\" xlink:type=\"simple\">https:\/\/www.finlex.fi\/fi\/laki\/ajantasa\/2004\/20041224#O2L6P7b<\/ext-link>."},{"key":"ref40","first-page":"3896","article-title":"Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis","volume":"56","author":"AOE Analysis","year":"2007","journal-title":"Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis"},{"key":"ref41","first-page":"24","article-title":"Long-Term Real-Life Experience With Rituximab in Adult Finnish Patients With Rheumatoid Arthritis Refractory or With Contraindication to Anti\u2013Tumor Necrosis Factor Drugs","volume":"21","author":"H Valleala","year":"2015","journal-title":"Long-Term Real-Life Experience With Rituximab in Adult Finnish Patients With Rheumatoid Arthritis Refractory or With Contraindication to Anti\u2013Tumor Necrosis Factor Drugs"},{"key":"ref42","first-page":"29","article-title":"Mortality in rheumatoid arthritis over the last fifty years: Systematic review","volume":"80","author":"S Dadoun","year":"2013","journal-title":"Mortality in rheumatoid arthritis over the last fifty years: Systematic review"},{"key":"ref43","article-title":"Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis","author":"JF Baker","journal-title":"Ann Rheum Dis 2016:annrheumdis\u2013 2016\u2013209463"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0220142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:24:48Z","timestamp":1589019888000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0220142"}},"subtitle":[],"editor":[{"given":"Monali S.","family":"Malvankar-Mehta","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0220142","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]}}}